217 related articles for article (PubMed ID: 9266440)
41. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
42. Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel.
Lee RT; Oster MW; Balmaceda C; Hesdorffer CS; Vahdat LT; Papadopoulos KP
Ann Oncol; 1999 Oct; 10(10):1245-7. PubMed ID: 10586344
[TBL] [Abstract][Full Text] [Related]
43. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.
Akerley W; Sikov WM; Cummings F; Safran H; Strenger R; Marchant D
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-87-S17-90. PubMed ID: 9374102
[TBL] [Abstract][Full Text] [Related]
44. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
Tamura T; Sasaki Y; Nishiwaki Y; Saijo N
Jpn J Cancer Res; 1995 Dec; 86(12):1203-9. PubMed ID: 8636011
[TBL] [Abstract][Full Text] [Related]
45. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.
Berger T; Malayeri R; Doppelbauer A; Krajnik G; Huber H; Auff E; Pirker R
Eur J Cancer; 1997 Aug; 33(9):1393-9. PubMed ID: 9337680
[TBL] [Abstract][Full Text] [Related]
46. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
47. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
Speck RM; Sammel MD; Farrar JT; Hennessy S; Mao JJ; Stineman MG; DeMichele A
J Oncol Pract; 2013 Sep; 9(5):e234-40. PubMed ID: 23943894
[TBL] [Abstract][Full Text] [Related]
48. Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
Vahdat L; Papadopoulos K; Lange D; Leuin S; Kaufman E; Donovan D; Frederick D; Bagiella E; Tiersten A; Nichols G; Garrett T; Savage D; Antman K; Hesdorffer CS; Balmaceda C
Clin Cancer Res; 2001 May; 7(5):1192-7. PubMed ID: 11350883
[TBL] [Abstract][Full Text] [Related]
49. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
50. Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Serra P; Tienghi A; Ravaioli A; Gentile A; Salzano E
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):30-3. PubMed ID: 9144688
[TBL] [Abstract][Full Text] [Related]
51. The effect of height on paclitaxel nerve damage.
Openshaw H; Beamon K; Longmate J; Synold T; Slatkin NE; Somlo G
J Neurooncol; 2005 Sep; 74(2):207-10. PubMed ID: 16193394
[TBL] [Abstract][Full Text] [Related]
52. Cold therapy to prevent paclitaxel-induced peripheral neuropathy.
Griffiths C; Kwon N; Beaumont JL; Paice JA
Support Care Cancer; 2018 Oct; 26(10):3461-3469. PubMed ID: 29681015
[TBL] [Abstract][Full Text] [Related]
53. Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.
Hertz DL; Kidwell KM; Vangipuram K; Li F; Pai MP; Burness M; Griggs JJ; Schott AF; Van Poznak C; Hayes DF; Lavoie Smith EM; Henry NL
Clin Cancer Res; 2018 Aug; 24(15):3602-3610. PubMed ID: 29703818
[No Abstract] [Full Text] [Related]
54. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies.
Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Kalofonos HP; Chroni E
J Neurol; 2005 Dec; 252(12):1459-64. PubMed ID: 16284715
[TBL] [Abstract][Full Text] [Related]
55. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
[TBL] [Abstract][Full Text] [Related]
56. The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.
Fukada I; Ito Y; Kobayashi K; Shibayama T; Takahashi S; Horii R; Akiyama F; Iwase T; Ohno S
PLoS One; 2017; 12(9):e0184322. PubMed ID: 28898275
[TBL] [Abstract][Full Text] [Related]
57. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Ghoreishi Z; Keshavarz S; Asghari Jafarabadi M; Fathifar Z; Goodman KA; Esfahani A
BMC Cancer; 2018 Oct; 18(1):958. PubMed ID: 30290775
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial.
Aghili M; Zare M; Mousavi N; Ghalehtaki R; Sotoudeh S; Kalaghchi B; Akrami S; Esmati E
Breast J; 2019 Mar; 25(2):226-231. PubMed ID: 30773731
[TBL] [Abstract][Full Text] [Related]
59. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone.
Lee JJ; Low JA; Croarkin E; Parks R; Berman AW; Mannan N; Steinberg SM; Swain SM
J Clin Oncol; 2006 May; 24(13):2084-91. PubMed ID: 16648510
[TBL] [Abstract][Full Text] [Related]
60. Profound and persistent painful paclitaxel peripheral neuropathy in a premenopausal patient.
Quintyne KI; Mainstone P; McNamara B; Boers P; Wallis F; Gupta RK
BMJ Case Rep; 2011 May; 2011():. PubMed ID: 22696717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
